RESEARCH REPORT Leah Lawrence A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association.
RESEARCH REPORT Leah Lawrence Even those renal cell carcinomas (RCCs) that are smaller than 4 cm may put patients at risk for aggressive cancer, according to a new study presented at the 28th Annual European Association of Urology Congress in Milan, Italy.
REVIEW ARTICLE Janice P. Dutcher, et al;ONCOLOGY Vol. 26 No. 6 In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non–clear cell RCC.
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
• Improving Harmonious Precision • Targeted Therapy for Cancer: Asking the Right Questions
A 56-year-old man with renal cell carcinoma developed widely metastatic disease post nephrectomy, for which he was receiving cyclic sunitinib therapy (50 mg daily for 4 weeks, followed by a 2-week rest period). Toward the end of his second cycle of therapy, he developed minimally pruritic, bright red erythema and fine scale involving both sides of the scrotum.
A 71-year-old, previously healthy male, presents for evaluation of a new, solitary, painless, pedunculated bump on his chin. Past medical history is negative for surgery or transfusion, and he denies intravenous drug use. His review of systems is negative with the exception of complaints about mild right-sided postero-lateral flank pain.
A 15-year-old male, who carries the diagnosis of von Hipple-Lindau Syndrome, has been followed routinely with CT scans. A mass was subsequently found in the left kidney and the following image was viewed.
The use of statins was independently associated with improvements in overall survival and disease-specific survival among a group of patients who had undergone partial or radical nephrectomy for renal... More »
High levels of physical activity were linked with a 22% decreased risk for renal cancer, according to a meta-analysis that looked at results from 19 studies that quantified the relationship with... More »
A trial comparing axitinib to sorafenib as first-line therapy for metastatic renal cell carcinoma showed a statistically significant improvement in progression-free survival for the drug; however, the... More »
CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.